Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 185

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 1B
Chunk 185
---
 stock options and restricted   stock awards

        —

        52,533

        Total

        11,423,193

        10,759,074

12. 401(k) Savings Plan 

The Company established a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code of 1986, as amended. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. Beginning in 2021, the Company makes matching contributions of up to 3% of the eligible employees’ compensation to the 401(k) plan. During the years ended December 31, 2024 and 2023, the Company made contributions to the 401(k) plan of $0.5 million and $0.6 million, respectively. 

13. Segment ReportingOperating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (CODM), in deciding how to allocate resources to an individual segment and in assessing performance. The Company’s CODM is its chief executive officer. Based on the information used by the CODM to allocate resources, the Company has determined it operates in one segment. The Company’s operating segment generates revenue from its development agreement with Toray, Genmab, and Innovent, as described in Note 6.The CODM assesses performance for the Company’s operating segment and decides how to allocate resources based on the Company’s cash runway and Net Loss that also is reported on the Consolidated Statements of Operations and Comprehensive Loss Income as Net Loss. Net loss is used to monitor budget versus actual results. The measure of segment assets is reported on the balance sheets as total assets.As of December 31, 2024 and 2023, all of the Company’s property and equipment was maintained in the United States. 

113

For the year ended December 31, 2024 and 2023, all of the Company’s revenue was generated and incurred in the United States. Please refer to the consolidated financial statements for further information related to these measures of segment performance. In addition, research and development and general and administrative expenses are significant segment expenses regularly provided to the CODM with the following categories: 

        Years Ended December 31,

        2024

        2023

        (In thousands)

        Significant Segment Expenses:

        Personnel related costs

        23,